VERAXA Biotech (NASDAQ: VRXA) is broadening its use of human-relevant preclinical testing methods across its antibody-based cancer drug development programs, a move that could improve the translation of research findings into clinical therapies and reduce reliance on animal testing. The company is implementing New Approach Methodologies (NAMs), including three-dimensional tumor spheroid models and patient-derived tumor models, to support its BiTAC(R) T-cell engagers, antibody-drug conjugates and bispecific antibody-drug conjugates.
In a recent ex vivo study, VERAXA reported that its lead BiTAC T-cell engager demonstrated selective, potent T-cell-mediated tumor-cell killing across 10 patient-derived non-small cell lung cancer models, while relevant controls showed minimal activity. The study required approximately 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies, according to the company.
The findings support VERAXA's dual-targeting approach, which is designed to direct immune activity toward cancer cells expressing two selected targets, and its broader strategy of using human-relevant models in preclinical research. By leveraging patient-derived models, the company aims to generate data that more closely reflects human tumor biology, potentially increasing the predictive value of preclinical studies and reducing the risk of late-stage clinical failures.
For investors, the expansion of NAMs could signal a more efficient path to clinical development for VERAXA's pipeline of antibody-based therapeutics. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Founded on scientific breakthroughs made at the European Molecular Biology Laboratory, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
The shift toward human-relevant testing methods also aligns with broader industry and regulatory trends toward reducing animal use in drug development. If VERAXA's NAMs approach proves successful, it could serve as a model for other biotech companies seeking to streamline preclinical research and improve the clinical relevance of their findings. The company's progress in this area may be closely watched by investors and industry observers alike.
To view the full article, visit https://ibn.fm/jZrd2. For regular updates about VERAXA Biotech, visit https://investors.veraxa.com. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
InvestorWire, a specialized communications platform, distributes press releases for private and public companies. It is part of the Dynamic Brand Portfolio at IBN, which offers editorial syndication to 5,000+ outlets and social media distribution to millions of followers.
